Send to

Choose Destination
See comment in PubMed Commons below
Neuroreport. 2003 Aug 6;14(11):1435-8.

Impaired degradation of PKCalpha by proteasome in a cellular model of Huntington's disease.

Author information

  • 1Laboratory for Structural Neuropathology, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, 351-0198 Saitama, Japan.


In order to investigate any effect of mutant huntingtin aggregation on proteasome function and the degradation of proteins involved in the ubiquitin-proteasome pathway, we studied the degradation of PKCalpha in Neuro2a cells expressing either normal or mutant truncated huntingtin (HD 16Q and HD 150Q cells). We were able to show an elevation of polyubiquitinated PKCalpha in HD 150Q cells. PMA treatment of these cells revealed significant delay of PKCalpha degradation in comparison with control HD 16Q cells. Subcellular fractionation showed association of non-degraded PKCalpha with the membrane fraction of HD 150Q cells. Our data suggest an impairment of the degradation of PKCalpha in HD 150Q cells. This impairment is likely to be connected with the sequestration of proteasome on mutant huntingtin aggregates.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk